| 证券代码 | OASM.O |
| 证券名称 | Oasmia Pharmaceutical AB ADR |
| 证券类型 | 美国存托凭证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2015-10-23 |
| 首发价格(元) | 4.06 USD |
| 首发数量(股) | 2339200 |
| 首发募资额(元) | 9,497,152.00 USD |
| 首发主承销商 | Joseph Gunnar & Co.,Rodman & Renshaw a unit of H.C. Wainwright & |
| 货币单位 | 瑞典克朗 |
| 公司名称 | Oasmia Pharmaceutical AB |
| 注册地址 | 瑞典 |
| 办公地址 | Vallongatan 1, Uppsala, Sweden |
| 成立日期 | 1988-04-15 |
| 董事会主席 | Julian Aleksov |
| 公司属地 | Sweden 瑞典 |
| 公司网址 | www.oasmia.com |
| 电话 | +46 (18) 505440 |
| 传真 | +46 (18) 510873 |
| 公司简介 | Oasmia Pharmaceutical AB is a pharmaceutical company which develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatic which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. It is a pharmaceutical company focused on innovative treatments within human and animal oncology. Its product and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents. |